KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Intangibles (2018 - 2022)

Esperion Therapeutics' Intangibles history spans 5 years, with the latest figure at $56000.0 for Q4 2022.

  • For Q4 2022, Intangibles changed 0.0% year-over-year to $56000.0; the TTM value through Dec 2022 reached $56000.0, changed 0.0%, while the annual FY2022 figure was $56000.0, 0.0% changed from the prior year.
  • Intangibles reached $56000.0 in Q4 2022 per ESPR's latest filing, roughly flat from $56000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $56000.0 in Q1 2018 to a low of $56000.0 in Q1 2018.
  • Average Intangibles over 5 years is $56000.0, with a median of $56000.0 recorded in 2018.
  • The largest YoY upside for Intangibles was 0.0% in 2019 against a maximum downside of 0.0% in 2019.
  • A 5-year view of Intangibles shows it stood at $56000.0 in 2018, then changed by 0.0% to $56000.0 in 2019, then changed by 0.0% to $56000.0 in 2020, then changed by 0.0% to $56000.0 in 2021, then changed by 0.0% to $56000.0 in 2022.
  • Per Business Quant, the three most recent readings for ESPR's Intangibles are $56000.0 (Q4 2022), $56000.0 (Q4 2021), and $56000.0 (Q4 2020).